NCT02135289View on ClinicalTrials.gov

The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID

CompletedOBSERVATIONAL
Enrollment

9,160

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Inflammatory Bowel DiseaseCrohn DiseaseUlcerative ColitisTuberculosisImmune-mediated Inflammatory Disease
Trial Locations (1)

Unknown

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT02135289 - The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID | Biotech Hunter | Biotech Hunter